Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Share-based Compensation: 2019-2024

Historic Share-based Compensation for Kymera Therapeutics (KYMR) over the last 6 years, with Dec 2024 value amounting to $55.0 million.

  • Kymera Therapeutics' Share-based Compensation rose 6.03% to $15.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $59.2 million, marking a year-over-year increase of 13.70%. This contributed to the annual value of $55.0 million for FY2024, which is 27.58% up from last year.
  • As of FY2024, Kymera Therapeutics' Share-based Compensation stood at $55.0 million, which was up 27.58% from $43.1 million recorded in FY2023.
  • Kymera Therapeutics' 5-year Share-based Compensation high stood at $55.0 million for FY2024, and its period low was $5.2 million during FY2020.
  • For the 3-year period, Kymera Therapeutics' Share-based Compensation averaged around $44.5 million, with its median value being $43.1 million (2023).
  • Data for Kymera Therapeutics' Share-based Compensation shows a peak YoY skyrocketed of 381.16% (in 2021) over the last 5 years.
  • Yearly analysis of 5 years shows Kymera Therapeutics' Share-based Compensation stood at $5.2 million in 2020, then surged by 381.16% to $25.0 million in 2021, then surged by 42.08% to $35.5 million in 2022, then climbed by 21.53% to $43.1 million in 2023, then climbed by 27.58% to $55.0 million in 2024.